The Vall d'Hebron Research Institute (VHIR) and the NEN Association made official on 5 April the signing of the collaboration agreement between the two entities, which will last for three years. The Association will collaborate with VHIR in a research project led by Dr. Soledad Gallego Melcón, Head of Onco-paediatric Haematology Service, "Epigenetic regulators as new therapeutic targets in neuroblastoma," the principal investigator of which is Dr. Miguel F. Segura, of the http://en.vhir.org/portal1/grup-equip.asp?t=recerca-translacional-en-cancer-en-la-infancia-i-ladolescencia&s=recerca&contentid=186749 Translational Research in Child and Adolescent Cancer group.The NEN Association will make an economic contribution of 60,000 euros divided into three years, which VHIR will allocate to co-finance the hiring of a researcher in training for this project.With this agreement, the Association aims to provide families with the help and information that will allow them to face the diagnosis and process of the disease, inform those affected of the scientific advances in this disease, and collaborate and stimulate, in an economic and social level, the research aimed at the cure of the disease. Likewise, VHIR is committed to fostering, promoting and developing research and the scientific and technological knowledge in the field of health and life sciences within the strands of basic, clinical, epidemiological, public health, economic, and health services.The NEN association was created by a group of parents united for the firm determination to fight against the neuroblastoma and to support the medical community that strives to achieve the welfare of their children during the treatments.NeuroblastomaNeuroblastoma is an uncommon cancer of the sympathetic nervous system (the nervous network that sends messages from the brain through the body). It is an embryonic tumour and the mean age at diagnosis is 2 years, considering that 90% are diagnosed before the 5 years of age.Tumours can be formed in the nervous tissue of the adrenal gland (the most frequent location) but also in the neck, thorax, abdomen or pelvis. They can also be scattered in other areas or systems of the body, such as bones or bone marrow. In total, it represents 8-10% of paediatric tumours and it is estimated that 1 in 7,000 newborns are diagnosed.The team of Translational Research in Child and Adolescent Cancer group develops different research projects in Neuroblastoma aimed at the application of epigenetic therapies and also to the study of the efficacy of new experimental drugs